





碧云天生物技术/Beyotime Biotechnology 订货热线: 400-1683301或800-8283301 订货e-mail: order@beyotime.com 技术咨询: info@beyotime.com 网址: http://www.beyotime.com

肉桂酸(98%, HPLC)

产品编号	产品名称	包装
SM1047-10mM	肉桂酸(98%, HPLC)	$10\text{mM} \times 0.2\text{ml}$
SM1047-25mg	肉桂酸(98%, HPLC)	25mg
SM1047-100mg	肉桂酸(98%, HPLC)	100mg

产品简介:

▶ 化学信息:

IC 1 ID ID.		
中文名	肉桂酸	
英文名	Cinnamic acid	
中文别名	-	
	3-Phenylacrylic acid; β-Phenylacrylic acid;	
英文别名	Myricitrine; Phenylacrylic acid; Cinnamylic acid;	
	Isocinnamic acid	
来源	苏合香树 <i>Liquidambar orientalis</i> Mill.	
化合物类型	苯丙素类(Phenylpropanoids)>苯丙酸类	
化学式	C ₉ H ₈ O ₂	
分子量	148.16	
CAS号	S号 621-82-9	
纯度	98%, HPLC	
溶剂/溶解度	Ethanol: ≥ 50 mg/ml (337.47 mM)	
	DMSO: 50 mg/ml (337.47 mM)	
次/走而14 ₁ 1	2mg加入1.35ml DMSO,或者每1.48mg加入1ml DMSO,	
溶液配制	配制成10mM溶液。	

> 生物信息

产品描述	Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in gliob					
冷日 透的	melanoma, prostate and lung carcinoma cells.					
信号通路						
靶点	Cancer	_	_	_	_	
	Intervention					
IC ₅₀	1-4.5 mM	-	-	-	-	
	Treatment with Cinnamic acid (CINN) of various tumor cells of epithelial and neuroectodermal origin result in dose-dependent growth inhibition following a 3-day exposure. The inhibitory concentrations causing a 50% reduction in tumor-cell proliferation (IC50) are between 1.2 to 4.5 mM. It is also showed that 20 mM Cinnamic acid is needed to cause an IC50 in FS4 cells, i.e. 5 to 20 times more than for tumor cells. In addition to inhibiting tumor-cell proliferation, Cinnamic acid causes morphological changes consistent with melanocyte differentiation. Within 5 days of treatment with 5 mM Cinnamic acid, melanoma 1011 cells appear enlarged with a markedly increased cytoplasm-to-nuclear ratio and well organized cytoskeleton, developed long dendritic processes and became highly melanotic. The change in the capacity of Cinnamic acid -treated melanoma 1011, A375(M) and SKMEI28 cells to degrade and cross tissue barriers is assessed by an in vitro invasion assay using modified Boyden chambers with matrigel-coated filters. After 3 days of continuous treatment with Cinnamic acid, a dose-dependent loss of invasive capacity in 3 tested tumor lines is observed. Treatment with 5 mM Cinnamic acid results in 75-95% loss of invasiveness.					
体外研究						
体内研究	N/A					
临床实验	N/A					

参考文献:

1. Liu L, et al. Int J Cancer. 1995,62(3):345-50.

包装清单:

产品编号	产品名称	包装
SM1047-10mM	肉桂酸(98%, HPLC)	$10\text{mM} \times 0.2\text{ml}$
SM1047-25mg	肉桂酸(98%, HPLC)	25mg
SM1047-100mg	肉桂酸(98%, HPLC)	100mg
-	说明书	1份

保存条件:

-20℃保存,至少一年有效。固体粉末4℃保存,至少一个月有效。如果溶于非DMSO溶剂,建议分装后-80℃保存,预计6个月内有效。

注意事项:

- ▶ 本产品可能对人体有一定的毒害作用,请注意适当防护,以避免直接接触人体或吸入体内。
- ▶ 本产品仅限于专业人员的科学研究用,不得用于临床诊断或治疗,不得用于食品或药品,不得存放于普通住宅内。
- ▶ 为了您的安全和健康,请穿实验服并戴一次性手套操作。

使用说明:

- 1. 收到产品后请立即按照说明书推荐的条件保存。使用前可以在2,000-10,000g离心数秒,以使液体或粉末充分沉降至管底后再开盖使用。
- 2. 对于10mM溶液,可直接稀释使用。对于固体,请根据本产品的溶解性及实验目的选择相应溶剂配制成高浓度的储备液(母液)后使用。
- 3. 具体的最佳工作浓度请参考本说明书中的体外、体内研究结果或其它相关文献,或者根据实验目的,以及所培养的特定细胞和组织,通过实验进行摸索和优化。
- 4. 不同实验动物依据体表面积的等效剂量转换表请参考如下网页: https://www.beyotime.com/support/animal-dose.htm

Version 2022.04.25